Delforge, M. (., Rodriguez-Otero, P. (., Shah, N. (., Moshkovich, O. (., Braverman, J. (., Dhanda, D. (. S., . . . Munshi, N. (. C. (2023). Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Citación estilo ChicagoDelforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45, et al. Analysis of Patient-reported Experiences Up to 2 Years After Receiving Idecabtagene Vicleucel (ide-cel, Bb2121) for Relapsed or Refractory Multiple Myeloma: Longitudinal Findings From the Phase 2 KarMMa Trial. 2023.
Cita MLADelforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45, et al. Analysis of Patient-reported Experiences Up to 2 Years After Receiving Idecabtagene Vicleucel (ide-cel, Bb2121) for Relapsed or Refractory Multiple Myeloma: Longitudinal Findings From the Phase 2 KarMMa Trial. 2023.